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Abstract. Minimal residual disease (MRD) is derived from 
tumor-initiating cells (TICs) and is responsible for tumor 
relapse. Neuroblastoma is characterized by extreme tumor 
heterogeneity, and more than half of high-risk patients 
experience tumor relapse. To overcome tumor heterogeneity 
and achieve more sensitive detection of MRD, several sets 
of real-time RT-PCR markers have been reported for MRD 
monitoring in neuroblastoma patients from different centers. 
However, these markers vary across centers and are still 
being validated. In the present study, we validated the ability 
of 14 commonly used real-time RT-PCR markers to detect 
MRD based on their expression in neuroblastoma TICs, and 
we developed a novel MRD detection protocol, which scored 
the samples as MRD-positive when the expression of one of 
the 11 real-time RT-PCR markers (CHRNA3, CRMP1, DBH, 
DCX, DDC, GABRB3, GAP43, ISL1, KIF1A, PHOX2B and 
TH) exceeded the normal range. By using this protocol, we 
prospectively monitored MRD in 73 bone marrow (BM), 
12 peripheral blood stem cell and 8 peripheral blood samples 
from 14 neuroblastoma patients treated at a single center. We 
scored 100, 56, 56 and 57% BM cytology-positive, elevated 
vanillylmandelic acid (VMA), elevated homovanillic acid 
(HVA) and elevated neuron-specific enolase (NSE) samples as 
MRD-positive, respectively. MRD was also positive in 48, 45, 
46 and 43% of the BM cytology-negative and normal VMA, 
normal HVA and normal NSE samples, respectively. These 
results suggest that the present MRD detection protocol based 
on the expression of a set of 11 real-time RT-PCR markers 
in neuroblastoma TICs achieves sensitive MRD monitoring in 
neuroblastoma patients.
Introduction
Neuroblastoma is one of the most common solid tumors in 
children and accounts for ~15% of pediatric cancer-related 
deaths (1,2). Neuroblastoma cells originate from neural crest 
cells that are committed to the development of the sympa-
thetic nervous system, and display extreme heterogeneity 
ranging from spontaneous regression to malignant progres-
sion. Although the prognosis for neuroblastoma patients has 
improved considerably, <40% of high-risk patients can expect 
long-term survival (3). The majority of cancer-related deaths 
in neuroblastoma are due to tumor relapse caused by minimal 
residual disease (MRD).
Tumor-initiating cells (TICs) account for only a small 
population of tumor cells that generate the bulk of the tumor 
through continuous self-renewal and differentiation, and are 
found in a variety of cancers (4-6). TICs can persist as MRD 
locally in the primary tumor or distantly in the blood, bone 
marrow and metastatic organs (7,8). Neuroblastoma TICs 
were recently identified as spheres grown in serum-free non-
adherent culture and were shown to express stem cell markers, 
exhibit self-renewal, and form metastatic tumors in immuno-
deficient mice (9,10).
Sensitive detection of MRD is fundamental when monitoring 
the disease status and evaluating the treatment response (7,11). 
In acute lymphoblastic leukemia (ALL), MRD detection with 
real-time PCR is directed against tumor-specific junctions using 
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genomic DNA as a template. This sensitive MRD detection 
in ALL patients has revealed the most important prognostic 
factors and is used to stratify treatments in the clinic (12-14). 
In neuroblastoma, the rationale for introducing the current 
MRD detection protocols to stratify treatments in the clinic 
remains unclear (15,16). Since no recurrent fusion genes have 
been found in neuroblastoma cells, MRD detection in neuro-
blastoma patients requires well-defined real-time RT-PCR 
markers that can be assessed using cDNA as a template. 
Although ideal MRD markers should be exclusively expressed 
in neuroblastoma cells and not in normal cells, commonly 
used markers are selected by their ability to experimentally 
define a cut-off value that distinguishes neuroblastoma cells 
from normal cells.
Tyrosine hydroxylase (TH) was initially evaluated as a 
single marker for neuroblastoma MRD detection, but was 
hampered by its expression in normal cells (17-20). Paired-
like homeobox 2b (PHOX2B) was subsequently identified as 
a more specific single marker, but was not highly expressed 
in all neuroblastoma tumors (21). To overcome tumor hetero-
geneity and achieve more sensitive detection of MRD in 
neuroblastoma patients, several sets of multiple markers have 
been reported at different centers. Based on gene expression 
analyses in neuroblastoma tumors, Viprey et al (22) identified 
the following three markers: doublecortin (DCX), PHOX2B 
and TH, while Cheung et al (23) independently identified the 
following 8 markers: cyclin D1 (CCND1), collapsin response 
mediator protein 1 (CRMP1), dopa decarboxylase (DDC), 
GABA A receptor β3 (GABRB3), ISL LIM homeobox 1 
(ISL1), kinesin family member 1A (KIF1A), PHOX2B, and 
transforming acidic coiled-coil containing protein 2 (TACC2). 
Furthermore, Stutterheim et al (24) selected the following 
6 markers: cholinergic receptor, nicotinic, α3 (CHRNA3), 
dopamine β-hydroxylase (DBH), DDC, growth-associated 
protein 43 (GAP43), PHOX2B and TH. These MRD markers 
are currently being validated.
In the present study, we validated 14 commonly used 
real-time RT-PCR markers based on their expression in 
neuroblastoma TICs, and developed a novel MRD detection 
protocol. By using this protocol, we prospectively monitored 
MRD in 73 bone marrow (BM), 12 peripheral blood stem cell 
(PBSC), and 8 peripheral blood (PB) samples from 14 neuro-
blastoma patients treated at Kobe Children's Hospital, Japan, 
between November, 2010 and August, 2012.
Materials and methods
Patients and samples. Normal PB samples were obtained 
from three healthy volunteers. PB, PBSC and BM samples 
were obtained from 14 neuroblastoma patients who were 
treated at Kobe Children's Hospital between November, 2010 
and August, 2012. Written informed consent was obtained 
from the patients, and the study was approved by Kobe 
Children's Hospital Ethics Board. The samples were handled 
in accordance with the Guidelines for the Clinical Research of 
Kobe University Graduate School of Medicine. All PB, PBSC 
and BM samples were separated using Mono-Poly Resolving 
Medium (DS Pharma Biomedical, Osaka, Japan), and nucle-
ated cells were collected according to the manufacturer's 
instructions.
Neuroblastoma TICs. Human neuroblastoma BE(2)-C cells 
were obtained from the American Type Culture Collection 
(Manassas, VA, USA), and neuroblastoma TICs were isolated 
as spheres of BE(2)-C cells as described previously (25). 
Briefly, BE(2)-C cells were cultured at 37˚C (5% CO2 and 
95% air) in sphere medium consisting of Dulbecco's modi-
fied Eagle's medium (DMEM)/Ham's F12 (3:1) (Wako Pure 
Chemical-Industries, Osaka, Japan), 100 U/ml penicillin/strep-
tomycin (PC/SM) (Invitrogen), 2% B27 supplement (Life 
Technologies, Carlsbad, CA, USA), 40 ng/ml basic fibroblast 
growth factor (bFGF) (R&D Systems, Minneapolis, MN, 
USA) and 20 ng/ml epidermal growth factor (EGF) (R&D 
Systems). The cells were subcultured with non-enzymatic cell 
dissociation solution (Sigma, St. Louis, MO, USA) and main-
tained for more than 4 weeks in Ultra-Low Attachment culture 
dishes (Corning, Inc., Corning, NY, USA).
RNA extraction and cDNA synthesis. Total RNA from normal 
BM was obtained from Clonetech (Palo Alto, CA, USA). 
Total RNA from neuroblastoma TICs as well as PB, PBSC 
and BM samples was extracted with a TRIzol Plus RNA 
Purification kit (Life Technologies) according to the manufac-
turer's instructions. RNA integrity was evaluated by agarose 
gel electrophoresis. cDNA was synthesized from 1 (or 0.5) µg 
of total RNA using a Quantitect Reverse Transcription kit 
(Qiagen, Valencia, CA, USA) and diluted to a total volume of 
80 (or 40) µl.
Real-time RT-PCR. Real-time RT-PCR was performed using 
an ABI 7500 Fast Real-time PCR system (Applied Biosystems, 
Foster City, CA, USA) in a total volume of 15 µl consisting of 
7.5 µl of 2X FastStart Universal SYBR-Green Master (Roche, 
Mannheim, Germany), 1.5 µl each of 3 µM sense and anti-
sense primers, and 1 µl of the sample cDNA (corresponding to 
12.5 ng of total RNA). Each cDNA was amplified with a precy-
cling hold at 95˚C for 10 min, followed by 40 cycles at 95˚C for 
15 sec and 60˚C for 60 sec, and one cycle at 95˚C for 15 sec, 
60˚C for 60 sec, 95˚C for 15 sec and 60˚C for 15 sec. Each 
sample was analyzed in triplicate. To correct for differences 
in the amount of total RNA and in the efficiency of cDNA 
synthesis, the expression of each marker was calculated based 
on the relative standard curve method using β2-microglobulin 
(B2M) as an endogenous reference for normalization.
Primers. The following primers were used: GD2 synthase 
(B4GALNT1, NM_001478) 5'-CCAACTCAACAGGCAA 
CTACAA-3' (sense) and 5'-ATGTCCCTCGGTGGAG AAC-3' 
(antisense); CCND1 (NM_053056) 5'-GAAGATCGTCGC 
CACCTG-3' (sense) and 5'-GACCTCCTCCTCGCACTTC T-3' 
(antisense); CHRNA3 (NM_000743) 5'-TGAAATGGAACC 
CCTCTGAC-3' (sense) and 5'-GGAAATCCCCAACAGC 
ATT-3' (antisense); CRMP1 (NM_001014809) 5'-GAGTGC 
AGCCGACATCATC-3' (sense) and 5'-GGGCTCTCCA 
AAAACTAGGG-3' (antisense); DBH (NM_000787) 5'-GAC 
CCCAAGGATTACCTCATT-3' (sense) and 5'-GTTGATGGC 
CTCCAGTGAC-3' (antisense); DCX (NM_000555) 5'-CAT 
CCCCAACACCTCAGAAG-3' (sense) and 5'-GGAGGTTCC 
GTTTGCTGA-3' (antisense); DDC (NM_000790) 5'-GGA 
GAAGGGGGAGGAGTG-3' (sense) and 5'-CAGCCGATG 
GATCACTTTG-3' (antisense); GABRB3 (NM_000814) 
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5'-GGGTGTCCTTCTGGATCAATTA-3' (sense) and 5'-TTG 
TCAGCACAGTTGTGATCC-3' (ant isense); GAP43 
(NM_001130064) 5'-GAGGATGCTGCTGCCAAG-3' (sense) 
and 5'-GGCACTTTCCTTAGGTTTGGT-3' (antisense); ISL1 
(NM_002202) 5'-AAGGACAAGAAGCGAAGCAT-3' (sense) 
and 5'-TTCCTGTCATCCCCTGGATA-3' (antisense); KIF1A 
(NM_004321) 5'-CTTGGCGACATCACTGACAT-3' (sense) 
and 5'-GCT GGACAGGGCTGAGAG-3' (antisense); PHOX2B 
(NM_003924) 5'-CTACCCCGACATCTACACTCG-3' (sense) 
and 5'-CCTGCTTGCGAAACTTGG-3' (antisense); TACC2 
(NM_006997) 5'-CCCCACTATTCGCTCAGAAA-3' (sense) 
and 5'-GGGCTTCTATCCGCATGAT-3' (antisense); TH 
(NM_199292) 5'-GCCAAGGACAAGCTCAGG-3' (sense) 
and 5'-AGCGTGTACGGGTCGAACT-3' (antisense); and 
β2-microglobulin (B2M, NM_004048) 5'-TTCTGGCCTG 
GAGGCTATC-3' (sense) and 5'-TCAGGAAATTTGACTT 
TCCATTC-3' (antisense).
Standard curves. To mimic MRD-positive PB, PBSC and 
BM samples, total RNA from neuroblastoma TICs was seri-
ally diluted into total RNA from normal PB to yield a total 
amount of 1.0 µg. The resulting six-step 5-fold dilutions were 
converted to cDNA yielding 100, 20, 4, 0.8, 0.16 and 0.032% 
dilutions. To obtain a standard curve, the CT values for each 
marker were obtained from triplicate real-time RT-PCR and 
plotted against the logarithm of the % dilution/100. Due to 
slight expression of each marker in normal PB, we generated 
standard curves with R2 >0.90 for each marker by limiting the 
plotted points of the % dilution. The quantitative range was 
defined as the minimum % dilution that plotted to the standard 
curve or above.
Normal range. Based on the threshold defined by the European 
Study Group on MRD detection in ALL (ESG-MRD-ALL), 
the mean CT value of a normal sample -3 was set as the 
maximum CT value for the normal sample (12). The normal 
range was then defined as any value less than the % dilution 
of MRD that corresponded to the maximum CT value of the 
normal sample. If the mean CT value of the normal sample 
was >40, the normal range was defined as less than the % dilu-
tion of MRD that corresponded to the minimum % dilution of 
MRD in the quantitative range.
Results
Expression profile of real-time RT-PCR markers in neuro-
blastoma TICs. To achieve more sensitive detection of MRD, 
we first analyzed the expression of commonly used real-time 
RT-PCR markers in normal PB, normal BM and neuroblas-
toma TICs that were isolated as spheres of BE(2)-C cells (25). 
In addition to the 13 MRD markers that were collec-
tively reported by Viprey et al (22), Cheung et al (23) and 
Stutterheim et al (24), a well-examined MRD marker, 
B4GALNT1, was also included in the present study (26). 
When the expression of these 14 MRD markers were analyzed 
by real-time RT-PCR, CHRNA3, CRMP1, DBH, DCX, DDC, 
GABRB3, GAP43, ISL1, KIF1A, PHOX2B and TH were 
predominantly expressed in neuroblastoma TICs in which 
the mean CT value was >9.0 lower when compared with that 
in normal PB and BM (Table I). Considering the variation 
of the mean CT value for normal PB, BM and neuroblastoma 
TICs (12), B4GALNT1, CCND1 and TACC2 were excluded 
from the present study.
Table I. Expression profile of real-time RT-PCR markers in neuroblastoma TICs.
Gene name Normal PB Normal BM Neuroblastoma TICs
 (mean CT ± SD) (mean CT ± SD) (mean CT ± SD)
B4GALNT1 >40 31.593±0.382 25.535±0.122
CCND1 34.051±0.329 28.725±0.096 22.243±0.056
CHRNA3 >40 31.028±0.709 21.538±0.102
CRMP1 >40 34.863±0.957 21.779±0.103
DBH >40 >40 23.133±0.059
DCX >40 31.683±0.727 22.037±0.544
DDC >40 36.150±0.329 21.538±0.102
GABRB3 35.996±0.130 31.952±0.865 22.340±0.102
GAP43 35.639±0.922 31.828±0.920 19.777±0.010
ISL1 >40 >40 24.929±0.044
KIF1A >40 32.601±0.728 19.901±0.044
PHOX2B >40 >40 20.351±0.140
TACC2 >40 28.007±1.272 34.782±0.001
TH >40 32.741±1.224 18.666±0.034
PB, peripheral blood; BM, bone marrow; TICs, tumor-initiating cells. B4GALNT1. β-1,4 N-acetylgalactosaminyltransferase 1; CCND1, 
cyclin D1; CHRNA3, cholinergic receptor, nicotinic, α3; CRMP1, collapsin response mediator protein 1; DBH, dopamine β-hydroxylase; 
DCX, doublecortin; DDC, dopa decarboxylase; GABRB3, GABA A receptor β3; GAP43, growth-associated protein 43; ISL1, ISL LIM 
homeobox 1; KIF1A, kinesin family member 1A; PHOX2B, paired-like homeobox 2b; TACC2, transforming acidic coiled-coil containing 
protein 2; TH, tyrosine hydroxylase.
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Standard curves for real-time RT-PCR markers. To mimic the 
actual expression of neuroblastoma MRD markers in clinical 
samples as precisely as possible, we generated their standard 
curves by serially diluting neuroblastoma TICs into normal 
PB. The 11 MRD markers (CHRNA3, CRMP1, DBH, DCX, 
DDC, GABRB3, GAP43, ISL1, KIF1A, PHOX2B and TH) 
were amplified by real-time RT-PCR, and triplicate CT values 
for each MRD marker were plotted against the logarithm 
of the % dilution/100. Although the standard curve for the 
real-time RT-PCR assay should theoretically have R2>0.99, 
the actual R2 value is lower than expected due to slight expres-
sion in normal PB. In the present study, we generated the 
standard curve with R2>0.90 by limiting the plotted points of 
the % dilution (Table II). Accordingly, 5 points (100, 20, 4, 0.8 
and 0.16% dilution) were plotted against triplicate CT values 
for DCX, ISL1 and TH (Fig. 1). For CHRNA3, CRMP1, DBH, 
DDC, GABRB3, GAP43, KIF1A and PHOX2B, 6 points (100, 
20, 4, 0.8, 0.16 and 0.032% dilution) were used (Fig. 1).
Normal range of real-time RT-PCR markers. Although the 
quantitative range frequently reflects the portion of the standard 
curve in which the MRD levels can be accurately quantitated, 
we here defined the quantitative range as the minimum % dilu-
tion that was plotted to the standard curve or above. While 
DCX, ISL1 and TH had a quantitative range of ≥0.160% dilu-
tion, the quantitative range of CHRNA3, CRMP1, DBH, DDC, 
GABRB3, GAP43, KIF1A and PHOX2B was ≥0.032% dilu-
tion (Table II). To account for tumor heterogeneity, we set the 
maximum CT value for the PB/PBSC and BM samples as the 
mean CT value of the normal PB and BM cells -3, respectively, 
according to the threshold defined by ESG-MRD-ALL (12). 
The normal range for each MRD marker in the PB/PBSC and 
BM samples was then defined as less than the % dilution that 
corresponded to the maximum CT value for the PB/PBSC and 
BM samples, respectively. If the mean CT value in normal PB 
and BM cells was >40, the normal range was defined as less 
than the % dilution that corresponded to the minimum % dilu-
tion in the quantitative range. For the PB samples, the normal 
ranges of all MRD markers did not exceed the minimum 
% dilution in the quantitative range (Table II). For the BM 
samples, the normal ranges of DBH, ISL1, PHOX2B and TH 
did not exceed the minimum % dilution in the quantitative 
range, whereas the normal ranges of CHRNA3, CRMP1, DCX, 
DDC, GABRB3, GAP43 and KIF1A were determined to be 
<0.413, <0.207, <5.598, <0.051, <1.059, <0.694 and <0.351%, 
respectively (Table II).
MRD sample characteristics. All 93 MRD samples were 
obtained from 14 neuroblastoma patients (#1-14) who were 
prospectively treated at Kobe Children's Hospital between 
November, 2010 and August, 2012. Patients #1-10 developed 
primary tumors and were treated according to the Japan 
Neuroblastoma Study Group (JNBSG) protocol. Low-risk 
patient #1 was subjected to surgical therapy followed by 
watchful waiting. Low-risk patient #2 was treated with 
one course of the LI-A regimen (1.5 mg/m2 VCR and 
300 mg/m2 CPA). Intermediate-risk patient #3 was treated 
with one course of the LI-D regimen (1.5 mg/m2 VCR, 
900 mg/m2 CPA, 30 mg/m2 THP and 60 mg/m2 CDDP). 
High-risk patient #4 was treated with five courses of the 
05A3 regimen (2,400 mg/m2 CPA, 1.5 mg/m2 VCR, 40 mg/m2 
THP and 100 mg/m2 CDDP) followed by peripheral blood 
stem cell transplantation (PBSCT), radiation therapy and 
surgical therapy. High-risk patient #5 was treated with five 
courses of the 05A3 regimen followed by PBSCT and radia-
tion therapy. High-risk patient #6 was treated with one course 
of the 05A1 regimen (1,200 mg/m2 CPA, 1.5 mg/m2 VCR, 
40 mg/m2 THP and 100 mg/m2 CDDP) and four courses of 
the 05A3 regimen followed by PBSCT, radiation therapy and 
surgical therapy. High-risk patient #7 was treated with one 
course of the 05A1 regimen and four courses of the 05A3 
regimen followed by PBSCT and radiation therapy. High-risk 
patient #8 was treated with one course of the 05A1 regimen 
and four courses of the 05A3 regimen. High-risk patients #9 
Table II. Normal range of real-time RT-PCR markers.
    Normal range Normal range
Gene name Standard curve R2 Quantitative range (%) in PB/PBSC (%) in BM (%)
CHRNA3 CT = -3.69log (% dilution/100) + 22.28 0.969 ≥0.032 <0.032 <0.413
CRMP1 CT = -3.04log (% dilution/100) + 26.21 0.911 ≥0.032 <0.032 <0.207
DBH CT = -3.66log (% dilution/100) + 26.60 0.946 ≥0.032 <0.032 <0.032
DCX CT = -3.02log (% dilution/100) + 27.39 0.912 ≥0.160 <0.160 <5.598
DDC CT = -3.71log (% dilution/100) + 23.99 0.983 ≥0.032 <0.032 <0.051
GABRB3 CT = -3.43log (% dilution/100) + 25.00 0.948 ≥0.032 <0.032 <1.059
GAP43 CT = -3.34log (% dilution/100) + 24.37 0.966 ≥0.032 <0.032 <0.694
ISL1 CT = -3.71log (% dilution/100) + 25.36 0.985 ≥0.160 <0.160 <0.160
KIF1A CT = -4.40log (% dilution/100) + 22.43 0.962 ≥0.032 <0.032 <0.351
PHOX2B CT = -4.19log (% dilution/100) + 23.46 0.944 ≥0.032 <0.032 <0.032
TH CT = -3.78log (% dilution/100) + 22.13 0.987 ≥0.160 <0.160 <0.160
CHRNA3, cholinergic receptor, nicotinic, α3; CRMP1, collapsin response mediator protein 1; DBH, dopamine β-hydroxylase; DCX, double-
cortin; DDC, dopa decarboxylase; GABRB3, GABA A receptor β3; GAP43, growth-associated protein 43; ISL1, ISL LIM homeobox 1; 
KIF1A, kinesin family member 1A; PHOX2B, paired-like homeobox 2b; TH, tyrosine hydroxylase.
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and 10 were treated with one course of the 05A1 regimen and 
three courses of the 05A3 regimen. Patients #11-14 experienced 
tumor relapses and were subjected to salvage chemotherapy. 
Patient #11 had one course of the IREC regimen (300 mg/m2 
CPT-11, 300 mg/m2 VP-16, 240 mg/m2 CBDCA) and five 
courses of the topotecan/CPA regimen (3.75 mg/m2 topotecan, 
1,250 mg/m2 CPA). Patient #12 had three courses of the ICE 
regimen (6,000 mg/m2 IFO, 800 mg/m2 CBDCA, 500 mg/m2 
VP-16) and two courses of the CPT-11 regimen (125 mg/m2 
CPT-11) followed by bone marrow transplantation (BMT). 
Patient #13 had two courses of the CPT-11 regimen, six courses 
of IREC regimen, five courses of the topotecan/CPA regimen, 
and three courses of the topotecan/TMZ regimen (3.75 mg/m2 
topotecan, 750 mg/m2 TMZ). Patient #14 had three courses 
of the ICE regimen and two courses of the IREC regimen. 
All patients were subjected to MRD sampling as frequently as 
possible during the course of treatment (Fig. 2).
Expression profile of real-time RT-PCR markers in MRD 
samples. CHRNA3, CRMP1, DBH, DCX, DDC, GABRB3, 
GAP43, ISL1, KIF1A, PHOX2B and TH expression was deter-
mined by real-time RT-PCR in the 93 MRD (73 BM, 12 PBSC 
and 8 PB) samples. Each marker was scored as positive when 
its expression exceeded the normal range. The number of 
Figure 1. Standard curves for real-time RT-PCR markers. Triplicate CT values for CHRNA3, CRMP1, DBH, DCX, DDC, GABRB3, GAP43, ISL1, KIF1A, 
PHOX2B and TH were plotted against the logarithm of the % dilution/100.
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positive samples for each marker varied from 4 (GABRB3) 
to 33 (PHOX2B). PHOX2B and DBH seemed to be sensitive 
markers in the present BM samples (Table III). Although only 
a limited number of PBSC and PB samples were analyzed, the 
sensitivity of each marker also varied between the BM, PBSC 
and PB samples as described previously (24). Only KIF1A, 
DCX, CRMP1 and GABRB3 were able to detect MRD in the 
present PBSC and PB samples (Table III).
Comparison of the present MRD detection protocol with 
clinical examinations. To validate the applicability of a set 
of these 11 commonly used real-time RT-PCR markers to 
monitor MRD, we compared these results with BM cytology, 
urinary vanillylmandelic acid (VMA), urinary homovanillic 
acid (HVA) and serum neuron-specific enolase (NSE) data. 
BM cytology data were obtained from 73 MRD (73 BM) 
samples, whereas urinary VMA, urinary HVA, and serum 
NSE data were obtained from 89 MRD (71 BM, 10 PBSC, and 
8 PB) samples (Table IV). MRD was scored as positive when 
the expression of one of the 11 markers exceeded the normal 
range. Thus, 100, 56, 56 and 57% of BM cytology-positive 
(n=10), elevated VMA (>15 µg/mg Cr, n=45), elevated HVA 
(>30 µg/mg Cr, n=43), and elevated NSE (>20 ng/ml, n=49) 
samples were MRD-positive, respectively (Table IV). MRD 
was also positive in 48, 45, 46 and 43% of BM cytology-
negative (n=63), normal VMA (≤15 µg/mg Cr, n=44), normal 
HVA (≤30 µg/mg Cr, n=46), and normal NSE (≤20 ng/ml, 
n=40) samples, respectively (Table IV). As BM samples were 
obtained from at least two sites (left and right iliac crests), we 
also compared real-time RT-PCR results from the paired BM 
samples. Of the 23 pairs of BM cytology-negative samples, 
11 pairs were MRD-positive at only one site. The remaining 
12 pairs had identical results for both sites; 6 pairs were 
MRD-negative and 6 pairs MRD-positive.
Discussion
In the present study, we validated the ability of 14 commonly 
used real-time RT-PCR markers to detect neuroblastoma MRD 
based on their expression in neuroblastoma TICs. We then 
developed a novel MRD detection protocol and prospectively 
monitored MRD in 73 BM, 12 PBSC and 8 PB samples from 
14 neuroblastoma patients treated at Kobe Children's Hospital 
between November, 2010 and August, 2012. Compared to 
currently used protocols, our protocol had two advantages. 
First, it determined 11 real-time RT-PCR markers based on 
their expression in neuroblastoma TICs. Second, it calculated 
the expression of these markers using the relative standard curve 
method and scored their expression levels as % dilution.
Several sets of real-time RT-PCR markers have been 
reported for MRD monitoring in neuroblastoma patients. 
Neuroblastoma is characterized by extreme heterogeneity that 
is observed in three levels: i) between different patients, ii) 
between different tumors within a patient, and iii) between 
different cells within a tumor. Regarding the heterogeneity 
between different patients, highly variable expression of 
CHRNA3, DBH, DDC, GAP43, PHOX2B and TH was detected 
in tumor samples from 56 patients (24). In terms of the hetero-
geneity between different tumors within a patient, one of the 5 
MRD markers (CHRNA3, DDC, GAP43, PHOX2B and TH) 
showed a >10-fold difference in relative expression in 6 out of 
56 pairs of BM samples obtained from two different sites (27). 
Regarding heterogeneity between different cells within a 
tumor, Stutterheim et al (27) recently reported that GAP43 and 
Figure 2. MRD sample characteristics. Downward arrows indicate the time points of MRD sampling. Week 0 was defined as the time when the primary or 
recurrent tumor was diagnosed. Pt, patient. LR, low-risk; IR, intermediate-risk; HR, high-risk. P, primary tumor; R, recurrent tumor.
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TH expression differed by >10 CT values across subclones of 
the same neuroblastoma IMR-32 cells isolated by serial dilu-
tion. Due to the differential gene expression between whole 
tumor cells and TICs (9,25), we validated MRD markers based 
on their expression in neuroblastoma TICs instead of whole 
neuroblastoma cells used by previous studies. Accordingly, 
B4GALNT1, CCND1 and TACC2 were determined to be 
inappropriate MRD markers, even though they were selected 
by their ability to experimentally define a cut-off value with 
which to distinguish neuroblastoma cells from normal cells in 
previous studies (23,26).
Although most previous studies determined the expression 
of MRD markers by real-time RT-PCR using the comparative 
CT method, we hypothesized that standard curves generated 
by serially diluting neuroblastoma TICs into normal PB would 
reflect more accurate MRD marker expression in clinical 
samples. Therefore, we calculated MRD marker expression 
by the relative standard curve method and scored it as the 
% dilution. While previous studies recommended a set of 3, 
6 or 8 markers by which to detect MRD in neuroblastoma 
patients (22-24), we used a set of 11 MRD markers (CHRNA3, 
CRMP1, DBH, DCX, DDC, GABRB3, GAP43, ISL1, KIF1A, 
PHOX2B and TH). PHOX2B was the most sensitive MRD 
marker in the present BM samples. Among 40 PHOX2B-
negative BM samples, only 7 samples were positive for 
CRMP1, DBH, DDC, ISL1 and/or TH. Although CRMP1, 
DCX, GABRB3 and KIF1A were not as sensitive as PHOX2B 
in the BM samples, they were able to detect MRD in the present 
PB and PBSC samples. Consequently, a set of these 11 markers 
was able to detect MRD in more than 40% of the BM cytology-
negative, normal urinary VMA, normal urinary HVA and 
normal serum NSE samples analyzed in the present study.
In summary, the present MRD detection protocol based 
on the expression of a set of 11 real-time RT-PCR markers 
(CHRNA3, CRMP1, DBH, DCX, DDC, GABRB3, GAP43, 
ISL1, KIF1A, PHOX2B and TH) in neuroblastoma TICs 
achieved sensitive MRD monitoring in neuroblastoma patients 
who were prospectively treated at a single center.
Table III. Expression profile of real-time RT-PCR markers in 
MRD samples.
 BM sample PBSC sample PB sample
CHRNA3
  Positive 10   0 0
  Negative 63 12 8
CRMP1
  Positive 14   0 1
  Negative 59 12 7
DBH
  Positive 22   0 0
  Negative 51 12 8
DCX
  Positive   9   0 2
  Negative 64 12 6
DDC
  Positive 14   0 0
  Negative 59 12 8
GABRB3
  Positive   3   0 1
  Negative 70 12 7
GAP43
  Positive   9   0 0
  Negative 64 12 8
ISL1
  Positive 14   0 0
  Negative 55 11 7
KIF1A
  Positive 11   2 1
  Negative 62 10 7
PHOX2B
  Positive 33   0 0
  Negative 40 12 8
TH
  Positive 12   0 0
  Negative 61 12 8
MRD, minimal residual disease; BM, bone marrow; PBSC, periph-
eral blood stem cell; PB, peripheral blood; CHRNA3, cholinergic 
receptor, nicotinic, α3; CRMP1, collapsin response mediator pro-
tein 1; DBH, dopamine β-hydroxylase; DCX, doublecortin; DDC, 
dopa decarboxylase; GABRB3, GABA A receptor β3; GAP43, 
growth-associated protein 43; ISL1, ISL LIM homeobox 1; KIF1A, 
kinesin family member 1A; PHOX2B, paired-like homeobox 2b; TH, 
tyrosine hydroxylase.
Table IV. Comparison of the present MRD detection protocol 
with clinical examinations.
 MRD MRD
 Positive Negative
BM cytology
  Positive 10   0
  Negative 30 33
Urinary VMA
  >15 µg/mg Cr 25 20
  ≤15 µg/mg Cr 20 24
Urinary HVA
  >30 µg/mg Cr 24 19
  ≤30 µg/mg Cr 21 25
Serum NSE
  >20 ng/ml 28 21
  ≤20 ng/ml 17 23
MRD, minimal residual disease; BM, bone marrow; VMA, vanillyl-
mandelic acid; HVA, homovanillic acid; NSE, neuron-specific enolase.
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